Contextualising Single-Arm Ophthalmology Trials With Real-World Data: An Emulated Target Trial Comparing The Efficacy of Interventions For Neovascular Age-Related Macular Degeneration

Competing Interest Statement

AL is an employee of the US FDA, has received research funding from Novartis, Santen, Carl Zeiss Meditec, and has acted as a consultant for Genentech, Topcon, and Verana Health. The opinions expressed in this article are those of the author and do not reflect the view of the FDA or the United States government. PJP has received research funding from Bayer, UK, and has acted as a consultant for Bayer UK, Genentech, Novartis UK, and Roche. RS has received travel expenses from Allergan (AbbVie) and is a board member of Eye-Wise diagnostics. PT has received a grant from Novartis Pharmaceuticals. AT, PJP and CE received a proportion of their funding from the Department of Health NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.

Funding Statement

The ABC Trial was funded by the Special Trustees of Moorfields Eye Hospital. Novartis Pharmaceuticals awarded a grant to cover the costs for extracting and storing electronic health records, but were not involved in the study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The ABC trial was approved by the ethics committee at each clinical site with all patients giving written informed consent to participate. The Caldicott data protection guardian at each EHR site gave signed permission for the de-identifiable EHRs to be extracted for analysis.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes